US 12,168,699 B2
Anti-polymeric IgA antibodies and methods of use
Lisa Cavacini, Boston, MA (US); and Mark S. J. Klempner, Boston, MA (US)
Assigned to University of Massachusetts, Westborough, MA (US)
Appl. No. 17/598,385
Filed by University of Massachusetts, Westborough, MA (US)
PCT Filed Mar. 27, 2020, PCT No. PCT/US2020/025131
§ 371(c)(1), (2) Date Sep. 27, 2021,
PCT Pub. No. WO2020/205477, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/826,288, filed on Mar. 29, 2019.
Prior Publication US 2022/0144970 A1, May 12, 2022
Int. Cl. C07K 16/42 (2006.01)
CPC C07K 16/4241 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01)] 20 Claims
 
1. An isolated antibody that specifically binds polymeric immunoglobulin A (pIgA), wherein the antibody comprises the following complementarity determining regions (CDRs):
(a) a CDR-H1 comprising the amino acid sequence of GFTFSNYG (SEQ ID NO: 1);
(b) a CDR-H2 comprising the amino acid sequence of INRGGDRI (SEQ ID NO: 2);
(c) a CDR-H3 comprising the amino acid sequence of RGLYYYGSDYYFDY (SEQ ID NO: 3);
(d) a CDR-L1 comprising the amino acid sequence of GNIHNY (SEQ ID NO: 4);
(e) a CDR-L2 comprising the amino acid sequence of NAK (SEQ ID NO: 5); and
(f) a CDR-L3 comprising the amino acid sequence of HHYYSTPYT (SEQ ID NO: 6).